__________________________________________________________________________________________
Re: Global ID / Local ID: TH201411002296/ TH141100449 FU (2)
Thank you for reporting to us an adverse event related to Lilly product(s).
We would like to collect more information to better understanding the reported event.
Please respond to following question regarding the adverse event – hemoglobin level drop from 13.9 to 9.8, involving a female patient, aged 83, who was subscribed Forteo, reported the event to Lilly on 04-Nov-2014.
Please provide the informatoin for following:
1. Clarify thyroid test (CHS level) which test is reporter referring to?
____________________________________________________________________________
¬¬¬¬
____________________________________________________________________________
____________________________________________________________________________
2. Clarify if the patient was hospitalized on 02-Nov-2014 for a blood test, or when did patient hospitalization start.
____________________________________________________________________________
¬¬¬¬
____________________________________________________________________________
____________________________________________________________________________
3. Was any diagnosis made for the blood abnormal?
____________________________________________________________________________
¬¬¬¬
____________________________________________________________________________
____________________________________________________________________________
4. Provide concomitant medications.
____________________________________________________________________________
¬¬¬¬
____________________________________________________________________________
____________________________________________________________________________
5. Relatedness rationale.
____________________________________________________________________________
¬¬¬¬
____________________________________________________________________________
____________________________________________________________________________
6. Results of WBC, ANC, Hgb, MCV, Plt count prior to start of teriparatide, at time of hospitalization (prior to transfusion), and upon recovery.
____________________________________________________________________________
¬¬¬¬
____________________________________________________________________________
____________________________________________________________________________
7. Results of bone marrow biopsy if performed, abdominal imaging (for possible hepatosplenomegaly).
____________________________________________________________________________
¬¬¬¬
____________________________________________________________________________
____________________________________________________________________________
HCP’s signature:
Date:
__________________________________________________________________________________
For Eli Lilly internal use only
Date of Confirmation of FU request sent to HCP:
Name and Designation: